AMENDMENTS TO THE CLAIMS

Claims 1-41 (Canceled).

42. (Currently amended) A solid composition comprising: (1) an immediate release layer comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of two pharmaceutically acceptable antioxidants; and (2) a sustained release layer comprising an effective amount of pseudoephedrine or a pharmaceutically acceptable salt ~~thereof;~~thereof and ~~(3)~~ a pharmaceutically acceptable sustained release agent; wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

43. (Previously presented) The solid composition of claim 42 wherein the two pharmaceutically acceptable antioxidants are edetate disodium and citric acid.

44. (Currently amended) A solid composition comprising: (1) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable ~~excipient;~~antioxidant; and (2) a sustained release second layer comprising an effective amount of pseudoephedrine or a pharmaceutically acceptable salt ~~thereof;~~thereof and ~~(3)~~ a pharmaceutically acceptable sustained release agent; wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

45. (Previously presented) A solid composition comprising: (1) an immediate release first layer comprising about 2.5 mg of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant; (2) a sustained release second layer comprising about 120 mg of pseudoephedrine or a pharmaceutically acceptable salt thereof; and (3) a pharmaceutically acceptable excipient.

46. (Currently amended) The solid composition of claim 45 wherein the total amount of desloratadine degradation products is less than or equal to ~~about~~ 2% by weight.

47. (Previously presented) The solid composition of claim 45 wherein a desloratadine-protective amount of a pharmaceutically acceptable binder is present in the sustained release second layer.

48. (Currently amended) The solid composition of claim 45 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37°C in about 45 minutes.

49. (Currently amended) The solid composition comprising a first and a second layer wherein the first layer is an immediate release layer wherein the ingredients comprise:

INGREDIENT	**mg/composition**
Desloratadine, micronized	5.0
Corn Starch NF/Ph.Eur.	36.0
Microcrystalline Cellulose NF/Ph.Eur./JP	140.7
Edetate Disodium	10.0
Citric Acid	2.0
Talc USP/Ph.Eur.	6.0
Dye ~~FD&C Blue No. 2 Aluminium Lake 5627~~	0.30
TOTAL	200.00

and wherein the second layer is a sustained release layer wherein the ingredients comprise:

INGREDIENT	**mg/composition**
Pseudoephedrine Sulfate USP	120.0
Hydroxypropyl Methylcellulose 2208, 1000,00cps USP/Ph.Eur.	105.0
Microcrystalline Cellulose NF/Ph.Eur./JP	103.5
Hydroxypropyl Methylcellulose 2910	10.5
Edetate Disodium	3.5
Silicon Dioxide NF	5.0
Magnesium Stearate NF/Ph.Eur.JP(Non-Bovine)	2.5
TOTAL	350.0
TOTAL Tablet Weight	550.0

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

50. (Currently amended) A solid composition comprising a first layer and a second layer, wherein the first layer is an immediate release first layer wherein the ingredients comprise:

INGREDIENT	**mg/composition**
Desloratadine, micronized	2.5
Corn Starch	18.0
Microcrystalline Cellulose	~~71.22~~ 70.35
Edetate Disodium	5.0
Citric Acid	1.0
Talc	3.0
Dye ~~FD+C Blue No. 2 Aluminium Lake~~	0.28
TOTAL	100.00

and wherein the second layer is a sustained release layer wherein the ingredients comprise:

INGREDIENT	**mg/composition**
Pseudoephedrine Sulfate	120.0
Hydroxypropyl Methylcellulose 2208	105.0
Microcrystalline cellulose	103.5
Edetate Disodium	3.5
Hydroxypropyl Methylcellulose 2910	10.5
Silicon Dioxide	5.0
Magnesium stearate	~~2.0~~ 2.5
TOTAL	350.0

and wherein total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

51. (Currently amended) The solid composition of claim 50 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37°C in about 45 minutes.

52. (Previously presented) A method of treating allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 42.

53. (Previously presented) A method of treating the signs and symptoms of nasal congestion associated with allergic and inflammatory conditions of the upper or lower airway passages and

skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 42.

54. (Previously presented) A method of treating the signs and symptoms of nasal congestion associated with allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 44.

55. (Previously presented) A method of treating the signs and symptoms of nasal congestion associated with allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 45.

56. (Previously presented) A method of treating the signs and symptoms of nasal congestion associated with allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 50.

57. (Previously presented) A method of treating the signs and symptoms of urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 42.

58. (Previously presented) A method of treating the signs and symptoms of urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 44.

59. (Previously presented) A method of treating the signs and symptoms of urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 45.

60. (Previously presented) A method of treating the signs and symptoms of urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 49.

61. (Previously presented) A method of treating the signs and symptoms of urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 50.

62. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 42.

63. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 44.

64. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 45.

65. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 49.

66. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 50.

67. (Previously presented) A method of treating allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 44.

68. (Previously presented) A method of treating allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 45.

69. (Previously presented) A method of treating allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 49.

70. (Previously presented) A method of treating allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 50.

71. (Previously presented) A method of treating the signs and symptoms of nasal congestion associated with allergic and inflammatory conditions of the upper or lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 49.

72. (Previously presented) A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant.

73. (Currently amended) The solid composition of claim 72 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

74. (Currently amended) The solid composition of claim 72 wherein total amount of desloratadine degradation products is less than or equal to ~~about~~ 2% by weight.

75. (Previously presented) The solid composition of claim 72 wherein about 0.1% to about 10% of at least one pharmaceutically acceptable antioxidant is present.

76. (Previously presented) The solid composition of claim 72 wherein the anti-allergic effective amount of desloratadine is about 2.5 mg.

77. (Previously presented) The solid composition of claim 72 wherein the anti-allergic effective amount of desloratadine is about 5 mg.

78. (Previously presented) The solid composition of claim 72 wherein two pharmaceutically acceptable antioxidants are present.

79. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

80. (Currently amended) The solid composition of claim 79 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

81. (Previously presented) The solid composition of claim 79 wherein about 0.1% to about 10% of at least one pharmaceutically acceptable antioxidant is present.

82. (Previously presented) The solid composition of claim 79 wherein the anti-allergic effective amount of desloratadine is about 2.5 mg.

83. (Previously presented) The solid composition of claim 79 wherein the anti-allergic effective amount of desloratadine is about 5 mg.

84. (Previously presented) The solid composition of claim 79 wherein two pharmaceutically acceptable antioxidants are present.

85. (Canceled)

86. (Canceled)

87. (Canceled)

88. (Canceled)

89. (Currently amended) A solid composition comprising about 5 mg of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

90. (Currently amended) The solid composition of claim 89 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

91. (Cancelled)

92. (Cancelled)

93. (Currently amended) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph. Eur.	36.0
Microcrystalline Cellulose NF/Ph. Eur./JP	132.7
Edetate Disodium USP	10.0
Citric Acid Anhydrous, USP	10.0
Stearic Acid, NF.	6.0
Dye ~~FD&C Blue No. 2 Aluminium Lake 5627~~	0.3
TOTAL	200.0

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

94. (Currently amended) The solid composition of claim 93 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

95. (Currently amended) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch NF/Ph. Eur.	18.0

Microcrystalline Cellulose NF/Ph. Eur./JP	66.35
Edetate Disodium	5.0
Citric Acid	5.0
Stearic Acid USP/Ph. Eur.	3.0
Dye ~~FD&C Blue No. 2 Aluminium Lake 5627~~	0.15
TOTAL	100.00

and wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

96. (Currently amended) The solid composition of claim 95 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

97. (Previously presented) A method of treating allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 72.

98. (Previously presented) A method of treating urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 72.

99. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 72.

100. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of two pharmaceutically acceptable antioxidants, wherein total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

101. (Previously presented) The solid composition of claim 100 wherein the two pharmaceutically acceptable antioxidants are edetate disodium and citric acid.

102. (Currently amended) A solid composition comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable ~~excipient,~~antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to about 2% by weight.

103. (Previously presented) A solid composition comprising about 2.5 mg desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant.

104. (Currently amended) The solid composition of claim 103 wherein the total amout of desloratadine degradation products in the solid composition is no more than ~~about~~ 2% by weight.

105. (Currently amended) The solid composition of claim 103 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

106. (Currently amended) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph. Eur.	36.0
Microcrystalline Cellulose NF/Ph. Eur./JP	140.7
Edetate Disodium	10.0
Citric Acid	2.0
Talc NF/Ph. Eur.	6.0
Dye ~~FD&C Blue No. 2 Aluminium Lake 5627~~	0.3
TOTAL	200.0

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

107. (Currently amended) The solid composition of claim 106 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

108. (Currently amended) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	2.5

Corn Starch NF/Ph. Eur.	18.0
Microcrystalline Cellulose NF/Ph. Eur./JP	~~71.22~~ 70.35
Edetate Disodium	5.0
Citric Acid	1.0
Talc NF/Ph. Eur.	3.0
Dye ~~FD&C Blue No. 2 Aluminium Lake 5627~~	0.28
TOTAL	100.00

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to ~~about~~ 2% by weight.

109. (Currently amended) The solid composition of claim 108 wherein at least ~~about~~ 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

110. (Previously presented) A method of treating allergic or inflammatory conditions of the upper and lower airway passages and skin which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 100.

111. (Previously presented) A method of treating the urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 100.

112. (Previously presented) A method of treating the urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 102.

113. (Previously presented) A method of treating urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 103.

114. (Previously presented) A method of treating urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 106.

115. (Previously presented) A method of treating urticaria which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 108.

116. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 100.

117. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 102.

118. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 103.

119. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 106.

120. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 108.